News & Updates

The presence of acute kidney injury (AKI) during stroke appears to contribute to increased mortality, with AKI tending to progress to chronic kidney disease (CKD) even without the need for renal replacement therapy, a study has found.

In chronic hepatitis B (CHB) patients treated with pegylated interferon alpha (peg-IFN-α)-based interventions, lower levels of the HB core-related antigen (HBcrAg) and higher levels of the HB surface antibody (HbsAb) are associated with durable functional cure, a recent study has found,

Supplementation with lutein/zeaxanthin instead of beta carotene is safe and does not contribute to an increase in lung cancer risk while having a potential beneficial effect on the risk of progression to late age-related macular degeneration (AMD), according to data from the Age-Related Eye Disease Study 2 (AREDS2) study.

Children who grow in height fast appears to have a higher risk of islet autoimmunity (IAA) and rapid progression to type 1 diabetes (T1D), a study has found.

Adolescents with normal weight obesity (NMO) may present with several cardiometabolic risk factors, putting them at greater risk of developing vascular events or diabetes, suggests a recent study.

A real-world study during Hong Kong’s Omicron BA.2 wave showed that both molnupiravir and nirmatrelvir/ritonavir effectively lowered the risks of disease progression and all-cause mortality in hospitalized COVID-19 patients not requiring oxygen supplementation on admission. However, mortality risk reduction was larger with nirmatrelvir/ritonavir vs molnupiravir.

In the phase II NEOBLADE* trial, the addition of the multikinase** inhibitor nintedanib to neoadjuvant chemotherapy (CT) consisting of gemcitabine and cisplatin failed to improve pathological complete response (pCR) and progression-free survival (PFS) in individuals with locally advanced muscle-invasive bladder cancer (MIBC).

The anaplastic lymphoma kinase (ALK) inhibitor ceritinib delivers favourable antitumour activity in ALK-mutated nonsmall cell lung cancer (NSCLC) patients with active brain metastases and/or leptomeningeal disease, according to the phase II ASCEND-7 trial.